Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Shares Outstanding (Weighted Average) (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $36.2 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Shares Outstanding (Weighted Average) rose 13.68% year-over-year to $36.2 million, compared with a TTM value of $36.2 million through Sep 2021, up 13.68%, and an annual FY2020 reading of $32.9 million, up 1485.31% over the prior year.
  • Shares Outstanding (Weighted Average) was $36.2 million for Q3 2021 at Black Diamond Therapeutics, roughly flat from $36.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $36.2 million in Q3 2021 and bottomed at $2.0 million in Q1 2019.
  • Average Shares Outstanding (Weighted Average) over 3 years is $21.4 million, with a median of $29.8 million recorded in 2020.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 1485.31% in 2020, then increased 13.68% in 2021.
  • Year by year, Shares Outstanding (Weighted Average) stood at $2.1 million in 2019, then soared by 1485.31% to $32.9 million in 2020, then grew by 10.06% to $36.2 million in 2021.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BDTX at $36.2 million in Q3 2021, $36.2 million in Q2 2021, and $36.1 million in Q1 2021.